Skip to main content

Table 1

From: Interstitial lung disease in patients with scleroderma - Treatment with rituximab

 

Pat.1. Pre-RTX

Pat.1. Post-RTX

Pat.2. Pre-RTX

Pat.2. Post-RTX

Pat. 3. Pre-RTX

Pat.3. Post-RTX

Vital Cap (L)

1.94 (65.2%)

2.02 (68.5%)

1.08 (44.8%)

1.15 (48.3%)

1.43 (53.4%)

1.51 (56.7%)

FEV 1

1.75 (68.6%)

1.81 (71.6%)

1.08 (53.1%)

1.09 (54.5%)

1.12 (49.2%)

1.18 (52.2%)

FEV1/VC

90.35

89.69

99.91

94.86

78.38

78.15

TLCOc/VA (mol/min/Kpa)

1.20 (68%)

1.03 (59.2%)

0.93 (54.8%)

1.02 (60.6%)

1.20 (68.0%)

1.29 (73,8%)

PCO2 (mmHg)

44.1

42.8

32.6

40.2

33

35.1

PO2 (mmHg)

83

86

84

92

64

75

Sat O2 (%)

94.2

96.6

96.7

97.4

94.4

96.3